Lyra Therapeutics, Inc. (LYRA)

Market Cap	313.65M
Revenue (ttm)	1.68M
Net Income (ttm)	-68.88M
Shares Out	59.74M
EPS (ttm)	-1.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	471,327
Open	5.03
Previous Close	5.16
Day's Range	5.00 - 5.65
52-Week Range	2.36 - 6.79
Beta	0.23
Analysts	Strong Buy
Price Target	12.67 (+141.33%)
Earnings Date	May 10, 2024

About LYRA

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 1, 2020
• Employees: 88
• Stock Exchange: NASDAQ
• Ticker Symbol: LYRA

Financial Performance

In 2023, LYRA's revenue was $1.56 million, an increase of 14.31% compared to the previous year's $1.36 million. Losses were -$62.68 million, 13.4% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for LYRA stock is "Strong Buy." The 12-month stock price forecast is $12.67, which is an increase of 141.33% from the latest price.

Price Target

$12.67

(141.33% upside)

Analyst Consensus: Strong Buy